Investment

AfaSci is a privately-held corporation in the San Francisco Bay Area. The Company is now advancing its completed clinical Phase I drug candidate AFA-281 to clinical Phase II trials and expands the drug discovery pipeline through a Series A Round of funding, out-licensing, joint venture co-development, or outright acquisition.